SGEN - Seagen Inc. Stock Price and Quote

SGEN [NASD]

Index	-	P/E	-	EPS (ttm)	-3.46	Insider Own	0.30%	Shs Outstand	184.79M	Perf Week	-3.03%
Market Cap	25.89B	Forward P/E	-	EPS next Y	-2.48	Insider Trans	-14.71%	Shs Float	183.63M	Perf Month	-0.12%
Income	-636.80M	PEG	-	EPS next Q	-1.03	Inst Own	89.30%	Short Float / Ratio	1.63% / 3.20	Perf Quarter	6.21%
Sales	1.86B	P/S	13.89	EPS this Y	-210.10%	Inst Trans	-2.10%	Short Interest	3.00M	Perf Half Y	-22.79%
Book/sh	15.27	P/B	9.04	EPS next Y	30.40%	ROA	-17.50%	Target Price	162.57	Perf Year	0.52%
Cash/sh	9.40	P/C	14.68	EPS next 5Y	-	ROE	-21.60%	52W Range	105.43 - 183.00	Perf YTD	5.63%
Dividend	-	P/FCF	-	EPS past 5Y	-30.10%	ROI	-22.20%	52W High	-25.83%	Beta	0.59
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	30.40%	Gross Margin	79.20%	52W Low	28.75%	ATR	3.71
Employees	2675	Current Ratio	3.80	Sales Q/Q	20.30%	Oper. Margin	-33.80%	RSI (14)	52.38	Volatility	2.52% 2.90%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	35.90%	Profit Margin	-34.20%	Rel Volume	0.52	Prev Close	138.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 15 AMC	Payout	-	Avg Volume	938.08K	Price	135.74
Recom	2.10	SMA20	0.52%	SMA50	4.47%	SMA200	-5.77%	Volume	93,429	Change	-1.64%

Feb-06-23

Downgrade

SVB Securities

Outperform → Market Perform

$162 → $141

Nov-21-22

Initiated

Truist

Hold

$135

Oct-11-22

Upgrade

BMO Capital Markets

Market Perform → Outperform

$177 → $178

Jun-29-22

Initiated

Raymond James

Outperform

$220

Jun-24-22

Initiated

BMO Capital Markets

Market Perform

$169

Feb-10-22

Reiterated

Wolfe Research

Peer Perform

$195 → $146

Feb-10-22

Reiterated

SVB Leerink

Outperform

$179 → $155

Feb-10-22

Reiterated

RBC Capital Mkts

Sector Perform

$154 → $132

Feb-10-22

Reiterated

Piper Sandler

Neutral

$165 → $150

Feb-10-22

Reiterated

Needham

Buy

$200 → $180

Show Previous Ratings

Jan-19-23 02:21PM	Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer Business Wire
08:00AM	Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 Business Wire
Dec-28-22 09:20AM	We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn Simply Wall St.
Dec-20-22 08:00AM	Seagen to Present at the J.P. Morgan Healthcare Conference Business Wire
06:45AM	Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer Business Wire
06:45AM	Loading…
06:45AM	Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Dec-12-22 10:00AM	Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma Business Wire +6.32%
Dec-07-22 02:22PM	Seagen Inc.'s (NASDAQ:SGEN) Intrinsic Value Is Potentially 98% Above Its Share Price Simply Wall St.
Dec-01-22 08:30AM	Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting Business Wire
Nov-17-22 05:41AM	Institutional owners may consider drastic measures as Seagen Inc.'s (NASDAQ:SGEN) recent US$1.2b drop adds to long-term losses Simply Wall St.
Nov-11-22 12:25AM	Seagen names new CEO following May resignation of Clay Siegall American City Business Journals
Nov-10-22 01:12PM	Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma Business Wire -5.00%
09:00AM	Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancers (SITC) Annual Meeting Business Wire
07:05AM	Seagen Appoints Sandra M. Swain, M.D., to Board of Directors Business Wire
07:00AM	Seagen Names David R. Epstein as Chief Executive Officer and Director Business Wire
05:25PM	Loading…
Oct-27-22 05:25PM	Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM	Seagen Reports Third Quarter 2022 Financial Results Business Wire
Oct-25-22 10:02AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline Zacks
Oct-19-22 11:14AM	Investing in Seagen (NASDAQ:SGEN) five years ago would have delivered you a 116% gain Simply Wall St.
Oct-07-22 03:24AM	Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains? Zacks
Oct-06-22 08:00AM	Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022 Business Wire
Sep-27-22 08:00AM	Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv) Business Wire
Sep-26-22 08:00AM	Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors Business Wire
Sep-19-22 08:00AM	Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer Business Wire
Sep-12-22 08:55AM	Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer Business Wire
08:55AM	Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer PR Newswire
Sep-07-22 06:05PM	Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress Business Wire
08:00AM	Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference Business Wire
Aug-26-22 04:31PM	Merck's Rumored $40 Billion Seagen Takeover Hits A Snag On Price Investor's Business Daily -5.69%
Aug-24-22 09:03AM	Merck Looks Attractive, With or Without Seagen The Wall Street Journal
05:18PM	Loading…
Aug-15-22 05:18PM	Seagen loses arbitration decision against Japanese drugmaker Daiichi Sankyo American City Business Journals
08:19AM	Seagen Suffers Loss In Arbitration Dispute Over ADC Technology Benzinga
Aug-12-22 01:14PM	Seagen Statement on Outcome of Daiichi Sankyo Arbitration Business Wire
Aug-03-22 05:47PM	Video Highlights- Predicting the Next FDA Juul Crackdown and More: Join Stream and Sentieo in Fireside to Discuss Expert Call Platform IPO-Edge.com
Jul-28-22 05:15PM	Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:50PM	REPLAY- Predicting the Next FDA Juul Crackdown and More: Join Stream and Sentieo in Fireside to Discuss Expert Call Platform IPO-Edge.com
04:02PM	Seagen Reports Second Quarter 2022 Financial Results Business Wire
12:28PM	Predicting the Next FDA Juul Crackdown and More: Join Stream and Sentieo Thursday in Fireside to Discuss Expert Call Platform CorpGov.com
12:14PM	Merck Tops Profit Estimates on Strong Keytruda and Gardasil Sales Barrons.com
Jul-26-22 10:53AM	Predicting the Next FDA Crackdown and Guidance Cut: Join Stream and Sentieo Thursday in Fireside to Discuss Expert Call Platform IPO-Edge.com
10:01AM	Earnings Preview: Global Blood Therapeutics (GBT) Q2 Earnings Expected to Decline Zacks
07:30AM	Seagen shares positive data for bladder cancer drug; stock is up 2.5% MarketWatch
04:00AM	Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer Business Wire
04:00AM	Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer PR Newswire
Jul-18-22 10:16AM	We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn Simply Wall St. -5.73%
Jul-15-22 05:30PM	Merck Deal for Seagen Seen as Unlikely by Earnings Release The Wall Street Journal
Jul-13-22 09:55AM	Seattle Genetics (SGEN) Now Trades Above Golden Cross: Time to Buy? Zacks
Jul-12-22 09:56AM	Industry Experts to Inform Investments: Join Stream in Fireside Chat to Discuss New Expert Call Transcript Library July 28 at 2PM ET IPO-Edge.com
Jul-11-22 10:59AM	Biotech Stocks Are Up by Double Digits. Its Still a Bear Market. Barrons.com
Jul-08-22 08:00AM	Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022 Business Wire
Jul-07-22 10:21PM	Corrections & Amplifications The Wall Street Journal
04:45PM	Biotech Stocks Are Poised to Outperform for the Rest of 2022 Barrons.com
03:41PM	Twitter removing over 1 million spam accounts a day, Bed Bath & Beyond stock soars Yahoo Finance Video
02:24PM	Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More The Wall Street Journal
09:50AM	Merck in advanced talks to buy biotech company Seagen Yahoo Finance Video
05:19AM	Merck Is Now in Advanced Talks to Buy Cancer Biotech Seagen for $40 Billion: Report Barrons.com
Jul-06-22 10:25AM	These 2 Tech Winners Could Reach New Highs, Says Jim Cramer TipRanks
Jul-02-22 06:35AM	Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer Business Wire
Jul-01-22 09:07AM	Biotech Stocks Finally Rose in June. What Does It Mean? Barrons.com
Jun-30-22 12:00PM	Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy Zacks
Jun-21-22 01:25PM	SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know Benzinga
Jun-20-22 08:43AM	Seattle Genetics (SGEN) Moves 12.7% Higher: Will This Strength Last? Zacks
Jun-18-22 08:56AM	Are Investors Undervaluing Seagen Inc. (NASDAQ:SGEN) By 45%? Simply Wall St.
Jun-17-22 11:22AM	Merck Shows Takeover Interest In Seagen: WSJ Benzinga +12.72%
Jun-06-22 11:00AM	Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting Business Wire
11:00AM	Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting Business Wire
Jun-03-22 03:12PM	ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma Business Wire
11:31AM	Ligand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound? Zacks
Jun-01-22 11:50AM	Why Is Axsome (AXSM) Down 30.3% Since Last Earnings Report? Zacks
May-26-22 05:25PM	Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma Business Wire
May-23-22 08:00AM	Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer Business Wire
May-16-22 02:02PM	Seagen CEO steps down after domestic violence arrest American City Business Journals +5.09%
06:00AM	Seagen Announces Resignation of President, Chairman & CEO Clay Siegall Business Wire
May-12-22 10:57AM	Recent 10.0% pullback isn't enough to hurt long-term Seagen (NASDAQ:SGEN) shareholders, they're still up 90% over 5 years Simply Wall St. +6.40%
May-09-22 04:33PM	Seagen CEO goes on leave amid domestic violence allegations American City Business Journals -11.85%
04:08PM	Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim Investor's Business Daily
06:00AM	Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence Business Wire
Apr-28-22 05:45PM	Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:02PM	Seagen Reports First Quarter 2022 Financial Results Business Wire
08:00AM	Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
Apr-22-22 12:14AM	Construction underway on Seagen biomanufacturing facility in Everett American City Business Journals
Apr-21-22 03:01PM	Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-20-22 09:00AM	Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines Business Wire
Apr-13-22 11:45AM	European Commission Approves PADCEV (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer PR Newswire
11:45AM	European Commission Approves PADCEV (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer Business Wire
Apr-08-22 03:23PM	Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo Business Wire
01:19PM	Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting Business Wire
Apr-07-22 08:00AM	Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022 Business Wire
Mar-16-22 06:30AM	Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates Business Wire
Mar-11-22 11:30AM	Why Is Seattle Genetics (SGEN) Up 12.7% Since Last Earnings Report? Zacks
Mar-01-22 08:00AM	Seagen to Present at the Cowen 42nd Annual Health Care Conference Business Wire
Feb-28-22 08:00AM	Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
08:00AM	Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer Business Wire
Feb-24-22 10:00AM	Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma Business Wire +5.57%
10:00AM	Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma Business Wire
Feb-16-22 05:20AM	Downgrade: Here's How Analysts See Seagen Inc. (NASDAQ:SGEN) Performing In The Near Term Simply Wall St.
Feb-14-22 05:00PM	Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy Business Wire
05:00PM	Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy PR Newswire
Feb-09-22 05:15PM	Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:02PM	Seagen Reports Fourth Quarter and Full Year 2021 Financial Results Business Wire

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DANSEY ROGER D	President, R&D & CMO	Feb 02	Sale	138.52	783	108,461	96,853	Feb 03 08:01 PM
LIU JEAN I	Chief Legal Officer	Jan 24	Option Exercise	39.15	5,000	195,750	90,113	Jan 26 07:39 PM
DANSEY ROGER D	President, R&D & CMO	Jan 24	Option Exercise	72.64	10,000	726,400	107,539	Jan 26 07:41 PM
DANSEY ROGER D	President, R&D & CMO	Jan 24	Sale	135.00	10,000	1,350,000	97,539	Jan 26 07:41 PM
LIU JEAN I	Chief Legal Officer	Jan 24	Sale	135.03	5,000	675,134	85,113	Jan 26 07:39 PM
LIU JEAN I	Chief Legal Officer	Jan 17	Sale	130.71	578	75,548	85,113	Jan 19 07:16 PM
LIU JEAN I	Chief Legal Officer	Jan 05	Option Exercise	39.15	4,525	177,154	90,216	Jan 06 07:08 PM
DANSEY ROGER D	President R&D & CMO	Jan 05	Option Exercise	72.64	7,500	544,800	105,039	Jan 06 07:10 PM
DANSEY ROGER D	President R&D & CMO	Jan 05	Sale	135.00	7,500	1,012,500	97,539	Jan 06 07:10 PM
LIU JEAN I	Chief Legal Officer	Jan 05	Sale	135.00	4,525	610,875	85,691	Jan 06 07:08 PM
LIU JEAN I	Chief Legal Officer	Jan 04	Option Exercise	39.15	475	18,596	86,166	Jan 06 07:08 PM
DANSEY ROGER D	President R&D & CMO	Jan 04	Option Exercise	72.64	2,500	181,600	100,039	Jan 06 07:10 PM
DANSEY ROGER D	President R&D & CMO	Jan 04	Sale	135.00	2,500	337,500	97,539	Jan 06 07:10 PM
LIU JEAN I	Chief Legal Officer	Jan 04	Sale	135.00	475	64,125	85,691	Jan 06 07:08 PM
ROMP CHARLES R	EVP, Commercial U.S.	Dec 20	Sale	127.63	1,129	144,094	58,475	Dec 21 06:48 PM
DANSEY ROGER D	President, Research and Develo	Dec 14	Option Exercise	77.16	10,000	771,628	106,942	Dec 16 07:42 PM
DANSEY ROGER D	President, Research and Develo	Dec 14	Sale	135.00	10,000	1,350,000	97,539	Dec 16 07:42 PM
Simonian Nancy A	Director	Dec 12	Option Exercise	36.70	8,750	321,125	62,753	Dec 14 05:49 PM
LIU JEAN I	Chief Legal Officer	Nov 17	Option Exercise	34.20	8,333	284,989	94,024	Nov 18 07:53 PM
LIU JEAN I	Chief Legal Officer	Nov 17	Sale	131.05	8,333	1,092,056	85,691	Nov 18 07:53 PM
LIU JEAN I	Chief Legal Officer	Nov 14	Option Exercise	76.86	1,301	99,995	85,691	Nov 16 06:22 PM
GRYSKA DAVID W	Director	Nov 11	Sale	129.10	7,500	968,220	40,253	Nov 15 05:46 PM
DANSEY ROGER D	Interim CEO & CMO	Oct 17	Option Exercise	74.54	10,000	745,421	102,146	Oct 19 07:17 PM
DANSEY ROGER D	Interim CEO & CMO	Oct 17	Sale	135.00	10,000	1,350,000	97,539	Oct 19 07:17 PM
SIMPSON TODD E	Chief Financial Officer	Aug 31	Sale	154.41	4,186	646,379	137,185	Sep 01 06:09 PM
ROMP CHARLES R	EVP, Commercial	Aug 31	Sale	154.41	1,133	174,952	59,604	Sep 01 06:06 PM
HIMES VAUGHN B	Chief Technical Officer	Aug 31	Sale	154.41	3,584	553,422	67,183	Sep 01 06:07 PM
LIU JEAN I	Chief Legal Officer	Aug 31	Sale	154.41	3,648	563,304	84,390	Sep 01 06:03 PM
DANSEY ROGER D	Interim CEO & CMO	Aug 31	Sale	154.41	5,019	775,006	97,539	Sep 01 06:03 PM
SIMPSON TODD E	Chief Financial Officer	Aug 16	Sale	170.22	1,967	334,813	141,371	Aug 17 09:19 PM
ROMP CHARLES R	EVP, Commercial	Aug 16	Sale	170.22	1,765	300,430	60,737	Aug 17 09:16 PM
LIU JEAN I	Chief Legal Officer	Aug 16	Sale	170.22	1,639	278,983	88,038	Aug 17 09:14 PM
HIMES VAUGHN B	Chief Technical Officer	Aug 16	Sale	170.22	1,527	259,918	70,767	Aug 17 09:13 PM
DANSEY ROGER D	Interim CEO & CMO	Aug 16	Sale	170.22	4,254	724,095	102,558	Aug 17 09:12 PM
ROMP CHARLES R	EVP, Commercial	Jul 05	Sale	179.46	712	127,776	48,771	Jul 07 06:50 PM
DANSEY ROGER D	Chief Medical Officer	Jun 28	Option Exercise	65.11	19,744	1,285,532	94,336	Jun 30 06:02 PM
DANSEY ROGER D	Chief Medical Officer	Jun 28	Sale	180.00	34,635	6,234,300	62,084	Jun 30 06:02 PM
HIMES VAUGHN B	Chief Technical Officer	Jun 17	Option Exercise	41.04	1,134	46,539	60,198	Jun 22 07:03 PM
HIMES VAUGHN B	Chief Technical Officer	Jun 17	Sale	160.00	1,134	181,440	119,471	Jun 22 07:03 PM
HIMES VAUGHN B	Chief Technical Officer	May 24	Option Exercise	26.10	10,866	283,603	67,359	May 26 06:07 PM
HIMES VAUGHN B	Chief Technical Officer	May 24	Sale	136.79	10,866	1,486,377	59,064	May 26 06:07 PM
ROMP CHARLES R	EVP, Commercial	May 16	Sale	134.21	333	44,691	49,483	May 18 07:34 PM
SIEGALL CLAY B	President & CEO	May 12	Option Exercise	26.10	17,043	444,822	676,653	May 13 07:13 PM
SIEGALL CLAY B	President & CEO	May 12	Sale	125.69	17,043	2,142,117	666,060	May 13 07:13 PM
DANSEY ROGER D	Chief Medical Officer	Apr 21	Sale	144.15	652	93,986	76,975	Apr 22 08:27 PM
SIEGALL CLAY B	President & CEO	Apr 20	Sale	144.32	1,885	272,041	666,060	Apr 22 08:34 PM
SIMPSON TODD E	Chief Financial Officer	Apr 20	Sale	144.32	567	81,829	127,891	Apr 22 08:32 PM
LIU JEAN I	Chief Legal Officer	Apr 20	Sale	144.32	401	57,872	75,946	Apr 22 08:31 PM
ROMP CHARLES R	EVP, Commercial	Apr 20	Sale	144.32	319	46,038	49,816	Apr 22 08:30 PM
HIMES VAUGHN B	Chief Technical Officer	Apr 20	Sale	144.32	574	82,839	59,064	Apr 22 08:29 PM
DANSEY ROGER D	Chief Medical Officer	Apr 20	Sale	144.32	787	113,579	77,627	Apr 22 08:27 PM
GRYSKA DAVID W	Director	Apr 19	Option Exercise	20.06	4,000	80,240	48,044	Apr 21 06:37 PM
GRYSKA DAVID W	Director	Apr 19	Sale	143.95	4,000	575,783	46,250	Apr 21 06:37 PM
SIEGALL CLAY B	President and CEO	Apr 07	Option Exercise	26.10	17,043	444,822	672,637	Apr 08 09:41 PM
SIEGALL CLAY B	President and CEO	Apr 07	Sale	154.23	17,043	2,628,610	667,945	Apr 08 09:41 PM
BAKER BROS. ADVISORS LP	Director	Mar 08	Option Exercise	20.06	35,000	702,100	42,965,004	Mar 10 04:39 PM
SIEGALL CLAY B	President & CEO	Mar 07	Option Exercise	26.10	17,043	444,822	674,588	Mar 09 07:42 PM
SIEGALL CLAY B	President & CEO	Mar 07	Sale	134.35	17,043	2,289,655	667,945	Mar 09 07:42 PM
HIMES VAUGHN B	Chief Technical Officer	Mar 03	Option Exercise	26.10	12,000	313,200	70,343	Mar 04 07:24 PM
HIMES VAUGHN B	Chief Technical Officer	Mar 03	Sale	127.05	12,000	1,524,558	59,500	Mar 04 07:24 PM
Simonian Nancy A	Director	Mar 02	Option Exercise	20.04	25,000	501,000	52,500	Mar 04 05:09 PM
GRYSKA DAVID W	Director	Feb 07	Option Exercise	20.06	4,500	90,270	48,621	Feb 09 06:58 PM
SIEGALL CLAY B	President & CEO	Feb 07	Option Exercise	26.10	17,043	444,822	676,930	Feb 09 07:02 PM
SIEGALL CLAY B	President & CEO	Feb 07	Sale	139.97	17,043	2,385,566	667,945	Feb 09 07:02 PM
GRYSKA DAVID W	Director	Feb 07	Sale	138.76	4,500	624,441	46,250	Feb 09 06:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience